Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/59650
CHANGES IN GLUCOSYLCERAMIDE STRUCTURE AFFECT VIRULENCE AND MEMBRANE BIOPHYSICAL PROPERTIES OF CRYPTOCOCCUS NEOFORMANS
Author
Affilliation
Department of Mycology. Institut Pasteur. Paris, France.
Department of Chemical and Biomolecular Engineering. Ohio University. Athens, USA.
Department of Chemistry and Biochemistry. Stony Brook University. Stony Brook, USA.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Departamento de Microbiologia Geral, Rio de Janeiro, RJ, Brazil.
Department of Chemistry and Biochemistry. Stony Brook University. Stony Brook, USA.
Department of Molecular Genetics and Microbiology. Stony Brook University. Stony Brook, USA.
Department of Molecular Genetics and Microbiology. Stony Brook University. Stony Brook, USA.
Fungal Pathogenesis Laboratory. Centre for Infectious Diseases and Microbiology. The Westmead Institute for Medical Research. Westmead, Australia.
Fungal Pathogenesis Laboratory. Centre for Infectious Diseases and Microbiology. The Westmead Institute for Medical Research. Westmead, Australia / Westmead Clinical School. University of Sydney at Westmead Hospital. Westmead, Australia / Marie Bashir Institute for Infectious Diseases and Biosecurity. University of Sydney, Australia.
Department of Chemistry and Biochemistry. Stony Brook University. Stony Brook, USA.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Departamento de Microbiologia Geral. Rio de Janeiro, RJ, Brazil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brazil.
Department of Chemistry and Biochemistry. Stony Brook University. Stony Brook, USA.
Department of Molecular Genetics and Microbiology. Stony Brook University. Stony Brook, USA / Veterans Administration Medical Center. Northport, USA / Division of Infectious Diseases. Stony Brook University. Stony Brook, USA.
Department of Chemical and Biomolecular Engineering. Ohio University. Athens, USA.
Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil.
Department of Chemical and Biomolecular Engineering. Ohio University. Athens, USA.
Department of Chemistry and Biochemistry. Stony Brook University. Stony Brook, USA.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Departamento de Microbiologia Geral, Rio de Janeiro, RJ, Brazil.
Department of Chemistry and Biochemistry. Stony Brook University. Stony Brook, USA.
Department of Molecular Genetics and Microbiology. Stony Brook University. Stony Brook, USA.
Department of Molecular Genetics and Microbiology. Stony Brook University. Stony Brook, USA.
Fungal Pathogenesis Laboratory. Centre for Infectious Diseases and Microbiology. The Westmead Institute for Medical Research. Westmead, Australia.
Fungal Pathogenesis Laboratory. Centre for Infectious Diseases and Microbiology. The Westmead Institute for Medical Research. Westmead, Australia / Westmead Clinical School. University of Sydney at Westmead Hospital. Westmead, Australia / Marie Bashir Institute for Infectious Diseases and Biosecurity. University of Sydney, Australia.
Department of Chemistry and Biochemistry. Stony Brook University. Stony Brook, USA.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Departamento de Microbiologia Geral. Rio de Janeiro, RJ, Brazil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brazil.
Department of Chemistry and Biochemistry. Stony Brook University. Stony Brook, USA.
Department of Molecular Genetics and Microbiology. Stony Brook University. Stony Brook, USA / Veterans Administration Medical Center. Northport, USA / Division of Infectious Diseases. Stony Brook University. Stony Brook, USA.
Department of Chemical and Biomolecular Engineering. Ohio University. Athens, USA.
Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil.
Abstract
Fungal glucosylceramide (GlcCer) is a plasma membrane sphingolipid in which the sphingosine backbone is unsaturated in carbon position 8 (C8) and methylated in carbon position 9 (C9). Studies in the fungal pathogen, Cryptococcus neoformans, have shown that loss of GlcCer synthase activity results in complete loss of virulence in the mouse model. However, whether the loss of virulence is due to the lack of the enzyme or to the loss of the sphingolipid is not known. In this study, we used genetic engineering to alter the chemical structure of fungal GlcCer and studied its effect on fungal growth and pathogenicity. Here we show that unsaturation in C8 and methylation in C9 is required for virulence in the mouse model without affecting fungal growth in vitro or common virulence factors. However, changes in GlcCer structure led to a dramatic susceptibility to membrane stressors resulting in increased cell membrane permeability and rendering the fungal mutant unable to grow within host macrophages. Biophysical studies using synthetic vesicles containing GlcCer revealed that the saturated and unmethylated sphingolipid formed vesicles with higher lipid order that were more likely to phase separate into ordered domains. Taken together, these studies show for the first time that a specific structure of GlcCer is a major regulator of membrane permeability required for fungal pathogenicity.
Share